Effective treatment of heavy and/or prolonged menstrual bleeding without organic cause: Pooled analysis of two multinational, randomised, double-blind, placebo-controlled trials of oestradiol valerate and dienogest

Ian S. Fraser, Susanne Parke, Uwe Mellinger, Andrea MacHlitt, Marco Serrani, Jeffrey Jensen

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Objectives To evaluate the efficacy of oestradiol valerate/dienogest (E2V/DNG) for the treatment of heavy and/or prolonged menstrual bleeding without organic pathology based on the analysis of data from two identically designed double-blind, randomised studies. Methods Women aged ≥18 years with heavy and/or prolonged menstrual bleeding were randomised to E2V/DNG (n = 269) or placebo (n = 152) for 196 days. Objective changes in menstrual blood loss (MBL) volume were assessed using the alkaline haematin method. Results After six months of treatment, median MBL decreased by 88% with E2V/DNG compared with 24% with placebo. The greatest reduction was achieved at the first withdrawal bleed after treatment initiation and it was sustained with no loss of effect throughout treatment. Conclusion E2V/DNG was more effective than placebo in reducing MBL in women with heavy and/or prolonged menstrual bleeding without organic pathology. The reduction was largely achieved as early as the first withdrawal bleed, with further gradual improvement throughout treatment.

Original languageEnglish (US)
Pages (from-to)258-269
Number of pages12
JournalEuropean Journal of Contraception and Reproductive Health Care
Volume16
Issue number4
DOIs
StatePublished - Aug 2011

Fingerprint

Placebos
Hemorrhage
Pathology
Therapeutics
Hemin
Blood Volume
Double-Blind Method
estradiol valerate-dienogest

Keywords

  • Heavy menstrual bleeding
  • Oral contraceptive

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Pharmacology (medical)
  • Reproductive Medicine

Cite this

@article{c30a3c363b7449e1b7ece7964925d71e,
title = "Effective treatment of heavy and/or prolonged menstrual bleeding without organic cause: Pooled analysis of two multinational, randomised, double-blind, placebo-controlled trials of oestradiol valerate and dienogest",
abstract = "Objectives To evaluate the efficacy of oestradiol valerate/dienogest (E2V/DNG) for the treatment of heavy and/or prolonged menstrual bleeding without organic pathology based on the analysis of data from two identically designed double-blind, randomised studies. Methods Women aged ≥18 years with heavy and/or prolonged menstrual bleeding were randomised to E2V/DNG (n = 269) or placebo (n = 152) for 196 days. Objective changes in menstrual blood loss (MBL) volume were assessed using the alkaline haematin method. Results After six months of treatment, median MBL decreased by 88{\%} with E2V/DNG compared with 24{\%} with placebo. The greatest reduction was achieved at the first withdrawal bleed after treatment initiation and it was sustained with no loss of effect throughout treatment. Conclusion E2V/DNG was more effective than placebo in reducing MBL in women with heavy and/or prolonged menstrual bleeding without organic pathology. The reduction was largely achieved as early as the first withdrawal bleed, with further gradual improvement throughout treatment.",
keywords = "Heavy menstrual bleeding, Oral contraceptive",
author = "Fraser, {Ian S.} and Susanne Parke and Uwe Mellinger and Andrea MacHlitt and Marco Serrani and Jeffrey Jensen",
year = "2011",
month = "8",
doi = "10.3109/13625187.2011.591456",
language = "English (US)",
volume = "16",
pages = "258--269",
journal = "European Journal of Contraception and Reproductive Health Care",
issn = "1362-5187",
publisher = "Informa Healthcare",
number = "4",

}

TY - JOUR

T1 - Effective treatment of heavy and/or prolonged menstrual bleeding without organic cause

T2 - Pooled analysis of two multinational, randomised, double-blind, placebo-controlled trials of oestradiol valerate and dienogest

AU - Fraser, Ian S.

AU - Parke, Susanne

AU - Mellinger, Uwe

AU - MacHlitt, Andrea

AU - Serrani, Marco

AU - Jensen, Jeffrey

PY - 2011/8

Y1 - 2011/8

N2 - Objectives To evaluate the efficacy of oestradiol valerate/dienogest (E2V/DNG) for the treatment of heavy and/or prolonged menstrual bleeding without organic pathology based on the analysis of data from two identically designed double-blind, randomised studies. Methods Women aged ≥18 years with heavy and/or prolonged menstrual bleeding were randomised to E2V/DNG (n = 269) or placebo (n = 152) for 196 days. Objective changes in menstrual blood loss (MBL) volume were assessed using the alkaline haematin method. Results After six months of treatment, median MBL decreased by 88% with E2V/DNG compared with 24% with placebo. The greatest reduction was achieved at the first withdrawal bleed after treatment initiation and it was sustained with no loss of effect throughout treatment. Conclusion E2V/DNG was more effective than placebo in reducing MBL in women with heavy and/or prolonged menstrual bleeding without organic pathology. The reduction was largely achieved as early as the first withdrawal bleed, with further gradual improvement throughout treatment.

AB - Objectives To evaluate the efficacy of oestradiol valerate/dienogest (E2V/DNG) for the treatment of heavy and/or prolonged menstrual bleeding without organic pathology based on the analysis of data from two identically designed double-blind, randomised studies. Methods Women aged ≥18 years with heavy and/or prolonged menstrual bleeding were randomised to E2V/DNG (n = 269) or placebo (n = 152) for 196 days. Objective changes in menstrual blood loss (MBL) volume were assessed using the alkaline haematin method. Results After six months of treatment, median MBL decreased by 88% with E2V/DNG compared with 24% with placebo. The greatest reduction was achieved at the first withdrawal bleed after treatment initiation and it was sustained with no loss of effect throughout treatment. Conclusion E2V/DNG was more effective than placebo in reducing MBL in women with heavy and/or prolonged menstrual bleeding without organic pathology. The reduction was largely achieved as early as the first withdrawal bleed, with further gradual improvement throughout treatment.

KW - Heavy menstrual bleeding

KW - Oral contraceptive

UR - http://www.scopus.com/inward/record.url?scp=79960721784&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79960721784&partnerID=8YFLogxK

U2 - 10.3109/13625187.2011.591456

DO - 10.3109/13625187.2011.591456

M3 - Article

C2 - 21774563

AN - SCOPUS:79960721784

VL - 16

SP - 258

EP - 269

JO - European Journal of Contraception and Reproductive Health Care

JF - European Journal of Contraception and Reproductive Health Care

SN - 1362-5187

IS - 4

ER -